JP6997627B2 - Cdk9阻害剤としての多環式アミド誘導体 - Google Patents
Cdk9阻害剤としての多環式アミド誘導体 Download PDFInfo
- Publication number
- JP6997627B2 JP6997627B2 JP2017567737A JP2017567737A JP6997627B2 JP 6997627 B2 JP6997627 B2 JP 6997627B2 JP 2017567737 A JP2017567737 A JP 2017567737A JP 2017567737 A JP2017567737 A JP 2017567737A JP 6997627 B2 JP6997627 B2 JP 6997627B2
- Authority
- JP
- Japan
- Prior art keywords
- pyridine
- chloro
- cyclohexanecarboxamide
- dihydro
- acetamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC1=IN=C(*)N1* Chemical compound CC1=IN=C(*)N1* 0.000 description 35
- AKIBGBJFUGFCIJ-GJZGRUSLSA-N CC(N[C@@H](CCC1)C[C@H]1C(Nc(nc1)cc(-c2c(CCCC3)[n]3nc2)c1Cl)=O)=O Chemical compound CC(N[C@@H](CCC1)C[C@H]1C(Nc(nc1)cc(-c2c(CCCC3)[n]3nc2)c1Cl)=O)=O AKIBGBJFUGFCIJ-GJZGRUSLSA-N 0.000 description 2
- PXSQNJOCKRDVAH-UHFFFAOYSA-N C(C1)CC11C(C2)CC2C1 Chemical compound C(C1)CC11C(C2)CC2C1 PXSQNJOCKRDVAH-UHFFFAOYSA-N 0.000 description 1
- IASRYLKZYZPWRV-UHFFFAOYSA-N C1COc2ccn[n]2C1 Chemical compound C1COc2ccn[n]2C1 IASRYLKZYZPWRV-UHFFFAOYSA-N 0.000 description 1
- TTXLSXAYPROAOR-CVEARBPZSA-N CC(C)(C)OC(N[C@@H](CCC1)C[C@@H]1C(OCc1ccccc1)=O)=O Chemical compound CC(C)(C)OC(N[C@@H](CCC1)C[C@@H]1C(OCc1ccccc1)=O)=O TTXLSXAYPROAOR-CVEARBPZSA-N 0.000 description 1
- PFWGSDKAJBSIAN-RRKGBCIJSA-N CC(C)(C)OC(N[C@H](CCC1)CC1C(Nc(nc1)cc(I)c1Cl)=O)=O Chemical compound CC(C)(C)OC(N[C@H](CCC1)CC1C(Nc(nc1)cc(I)c1Cl)=O)=O PFWGSDKAJBSIAN-RRKGBCIJSA-N 0.000 description 1
- SMXYHNZGXDWVCU-JKSUJKDBSA-N CC(C)(C)OC(N[C@H](CCC1)C[C@H]1C(Nc(nc1)cc(-c2c(CCCC3)[n]3nc2)c1Cl)=O)=O Chemical compound CC(C)(C)OC(N[C@H](CCC1)C[C@H]1C(Nc(nc1)cc(-c2c(CCCC3)[n]3nc2)c1Cl)=O)=O SMXYHNZGXDWVCU-JKSUJKDBSA-N 0.000 description 1
- MWDBQIXEASVAGD-JKSUJKDBSA-N CC(C)(C)OC(N[C@H](CCC1)C[C@H]1C(Nc(nc1)cc(-c2cnc3[n]2CC(C)(C)C3)c1Cl)=O)=O Chemical compound CC(C)(C)OC(N[C@H](CCC1)C[C@H]1C(Nc(nc1)cc(-c2cnc3[n]2CC(C)(C)C3)c1Cl)=O)=O MWDBQIXEASVAGD-JKSUJKDBSA-N 0.000 description 1
- LZZMWGNQVKORNC-ZWKOTPCHSA-N CC(C)(C)OC(N[C@H](CCC1)C[C@H]1C(Nc1nccc(-c2c(CC(C)(C)C3)[n]3nc2)c1)=O)=O Chemical compound CC(C)(C)OC(N[C@H](CCC1)C[C@H]1C(Nc1nccc(-c2c(CC(C)(C)C3)[n]3nc2)c1)=O)=O LZZMWGNQVKORNC-ZWKOTPCHSA-N 0.000 description 1
- ZFOLBBWSSGJMSR-MQWYWXNSSA-N CC(C)(C)OC1OC1N[C@H](CCC1)C[C@H]1C(Nc(nc1)cc(-c2cnc3[n]2CC(C)(C)C3)c1F)=O Chemical compound CC(C)(C)OC1OC1N[C@H](CCC1)C[C@H]1C(Nc(nc1)cc(-c2cnc3[n]2CC(C)(C)C3)c1F)=O ZFOLBBWSSGJMSR-MQWYWXNSSA-N 0.000 description 1
- WABCEBWEZXQSNR-UHFFFAOYSA-N CC(C)(C)[N](C)(C)OC(C)=O Chemical compound CC(C)(C)[N](C)(C)OC(C)=O WABCEBWEZXQSNR-UHFFFAOYSA-N 0.000 description 1
- BQSVXIAYEVCTTN-UHFFFAOYSA-N CC(C)(C)[Si](C)(C)OCC(C)(C)Cc1c(B2OC(C)(C)C(C)(C)O2)c[n][n]1COCC[Si](C)(C)C Chemical compound CC(C)(C)[Si](C)(C)OCC(C)(C)Cc1c(B2OC(C)(C)C(C)(C)O2)c[n][n]1COCC[Si](C)(C)C BQSVXIAYEVCTTN-UHFFFAOYSA-N 0.000 description 1
- VOWLJJMXCWLHFI-UHFFFAOYSA-N CC(C)(C)[Si](C)(C)OCC(C)(C)Cc1n[n](COCC[Si](C)(C)C)cc1I Chemical compound CC(C)(C)[Si](C)(C)OCC(C)(C)Cc1n[n](COCC[Si](C)(C)C)cc1I VOWLJJMXCWLHFI-UHFFFAOYSA-N 0.000 description 1
- QVTYLIOVXVMVDH-UHFFFAOYSA-N CC(C)(C1)CNC1=S Chemical compound CC(C)(C1)CNC1=S QVTYLIOVXVMVDH-UHFFFAOYSA-N 0.000 description 1
- LLZXUHXVGGEKBS-UHFFFAOYSA-N CC(C)(C1)C[n]2c1ncc2 Chemical compound CC(C)(C1)C[n]2c1ncc2 LLZXUHXVGGEKBS-UHFFFAOYSA-N 0.000 description 1
- QBEKPBSWONWPIV-MZPXATCKSA-N CC(C)(CC12)CN1N=CC2c1cc(NC([C@H](CCC2)C[C@@H]2N)=O)ncc1F Chemical compound CC(C)(CC12)CN1N=CC2c1cc(NC([C@H](CCC2)C[C@@H]2N)=O)ncc1F QBEKPBSWONWPIV-MZPXATCKSA-N 0.000 description 1
- CHRZVGRJOMIBAW-UONOGXRCSA-N CC(C)(CC[n]1nc2)Cc1c2-c(cc(NC([C@@H](CCC1)C[C@@H]1N)=O)nc1)c1F Chemical compound CC(C)(CC[n]1nc2)Cc1c2-c(cc(NC([C@@H](CCC1)C[C@@H]1N)=O)nc1)c1F CHRZVGRJOMIBAW-UONOGXRCSA-N 0.000 description 1
- BASCMEHCBVMWLO-UHFFFAOYSA-N CC(C)(C[n]1nccc1)C(O)=O Chemical compound CC(C)(C[n]1nccc1)C(O)=O BASCMEHCBVMWLO-UHFFFAOYSA-N 0.000 description 1
- UKLLTAUOQJXKKP-UHFFFAOYSA-N CC(C)(Cc([n](COCC[Si](C)(C)C)nc1)c1I)COC Chemical compound CC(C)(Cc([n](COCC[Si](C)(C)C)nc1)c1I)COC UKLLTAUOQJXKKP-UHFFFAOYSA-N 0.000 description 1
- MGAVCFAPDCHXER-UHFFFAOYSA-N CC(C)(Cc1n[nH]cc1)CO Chemical compound CC(C)(Cc1n[nH]cc1)CO MGAVCFAPDCHXER-UHFFFAOYSA-N 0.000 description 1
- UTFPNAXQQWJBHZ-WDEREUQCSA-N CC(C)OC([C@@H](CCC1)C[C@@H]1NC(C)=O)=O Chemical compound CC(C)OC([C@@H](CCC1)C[C@@H]1NC(C)=O)=O UTFPNAXQQWJBHZ-WDEREUQCSA-N 0.000 description 1
- YUKDUJGPVDOBHZ-TYKSMWHLSA-N CC(C1)CC1C(C[C@@H](C1)C(OCc2ccccc2)=O)C[C@H]1NC(OC(C)(C)C)=O Chemical compound CC(C1)CC1C(C[C@@H](C1)C(OCc2ccccc2)=O)C[C@H]1NC(OC(C)(C)C)=O YUKDUJGPVDOBHZ-TYKSMWHLSA-N 0.000 description 1
- FZFPAKGNEMHQAH-LSDHHAIUSA-N CC(N[C@H](CCC1)C[C@H]1C(Nc(cc1-c2c(CCCCO)[nH]nc2)ncc1Cl)=O)=O Chemical compound CC(N[C@H](CCC1)C[C@H]1C(Nc(cc1-c2c(CCCCO)[nH]nc2)ncc1Cl)=O)=O FZFPAKGNEMHQAH-LSDHHAIUSA-N 0.000 description 1
- AKIBGBJFUGFCIJ-LSDHHAIUSA-N CC(N[C@H](CCC1)C[C@H]1C(Nc(nc1)cc(-c2c(CCCC3)[n]3nc2)c1Cl)=O)=O Chemical compound CC(N[C@H](CCC1)C[C@H]1C(Nc(nc1)cc(-c2c(CCCC3)[n]3nc2)c1Cl)=O)=O AKIBGBJFUGFCIJ-LSDHHAIUSA-N 0.000 description 1
- CUVDIVXPUWFCOD-UONOGXRCSA-N CC(N[C@H](CCC1)C[C@H]1C(Nc(nc1)cc(-c2c(COCC3)[n]3nc2)c1Cl)=O)=O Chemical compound CC(N[C@H](CCC1)C[C@H]1C(Nc(nc1)cc(-c2c(COCC3)[n]3nc2)c1Cl)=O)=O CUVDIVXPUWFCOD-UONOGXRCSA-N 0.000 description 1
- WPQVVZCWYBJSFR-QMRHZFGWSA-N CC(N[C@H](CCC1)C[C@H]1C(Nc(nc1)cc(C2=C(CCC(C3)OC)N3NC2)c1Cl)=O)=O Chemical compound CC(N[C@H](CCC1)C[C@H]1C(Nc(nc1)cc(C2=C(CCC(C3)OC)N3NC2)c1Cl)=O)=O WPQVVZCWYBJSFR-QMRHZFGWSA-N 0.000 description 1
- ASEPZBUAEOJUCM-DLBZAZTESA-N CC(N[C@H](CCC1)C[C@H]1C(Nc1cc(-c2c(CCCC3)[n]3nc2)ccn1)=O)=O Chemical compound CC(N[C@H](CCC1)C[C@H]1C(Nc1cc(-c2c(CCCC3)[n]3nc2)ccn1)=O)=O ASEPZBUAEOJUCM-DLBZAZTESA-N 0.000 description 1
- BBWQZKXLQALAEA-UONOGXRCSA-N CC(N[C@H](CCC1)C[C@H]1C(Nc1cc(C)c(C)cn1)=O)=O Chemical compound CC(N[C@H](CCC1)C[C@H]1C(Nc1cc(C)c(C)cn1)=O)=O BBWQZKXLQALAEA-UONOGXRCSA-N 0.000 description 1
- BGQLJVGPVCMFTP-LSDHHAIUSA-N CC1(C)C[n]2c(-c(cc(NC([C@@H](CCC3)C[C@@H]3NC(C3(CC3)O)=O)=O)nc3)c3Cl)cnc2C1 Chemical compound CC1(C)C[n]2c(-c(cc(NC([C@@H](CCC3)C[C@@H]3NC(C3(CC3)O)=O)=O)nc3)c3Cl)cnc2C1 BGQLJVGPVCMFTP-LSDHHAIUSA-N 0.000 description 1
- SSTFWCHPJFZJHK-LSDHHAIUSA-N CC1(C)C[n]2c(-c3cc(NC([C@@H](CCC4)C[C@@H]4NC(C)=O)=O)ncc3F)cnc2C1 Chemical compound CC1(C)C[n]2c(-c3cc(NC([C@@H](CCC4)C[C@@H]4NC(C)=O)=O)ncc3F)cnc2C1 SSTFWCHPJFZJHK-LSDHHAIUSA-N 0.000 description 1
- XXPDEKKKGHCODA-UONOGXRCSA-N CC1(C)C[n]2ncc(-c(cc(NC([C@@H](CC3)C[C@@H]3NC(C)=O)=O)nc3)c3Cl)c2C1 Chemical compound CC1(C)C[n]2ncc(-c(cc(NC([C@@H](CC3)C[C@@H]3NC(C)=O)=O)nc3)c3Cl)c2C1 XXPDEKKKGHCODA-UONOGXRCSA-N 0.000 description 1
- WCCDPNHGMPXBNQ-DOTOQJQBSA-N CC1(C)C[n]2ncc(-c(cc(NC([C@@H](CCC3)C[C@@H]3NC(C)=O)=O)nc3)c3C#N)c2C1 Chemical compound CC1(C)C[n]2ncc(-c(cc(NC([C@@H](CCC3)C[C@@H]3NC(C)=O)=O)nc3)c3C#N)c2C1 WCCDPNHGMPXBNQ-DOTOQJQBSA-N 0.000 description 1
- OJMFGZGCGNGPDF-LSDHHAIUSA-N CC1(C)C[n]2ncc(-c(cc(NC([C@@H](CCC3)C[C@@H]3NC(C3(CC3)O)=O)=O)nc3)c3Cl)c2C1 Chemical compound CC1(C)C[n]2ncc(-c(cc(NC([C@@H](CCC3)C[C@@H]3NC(C3(CC3)O)=O)=O)nc3)c3Cl)c2C1 OJMFGZGCGNGPDF-LSDHHAIUSA-N 0.000 description 1
- XNBVUZHSZXDHAY-GOEBONIOSA-N CC1(C)C[n]2ncc(-c(cc(NC([C@@H](CCC3)C[C@@H]3NC(C3COC3)=O)=O)nc3)c3Cl)c2C1 Chemical compound CC1(C)C[n]2ncc(-c(cc(NC([C@@H](CCC3)C[C@@H]3NC(C3COC3)=O)=O)nc3)c3Cl)c2C1 XNBVUZHSZXDHAY-GOEBONIOSA-N 0.000 description 1
- BNMSUGRKZJRLFE-FUHWJXTLSA-N CC1(C)C[n]2ncc(-c3c(C)cnc(NC([C@@H](CCC4)C[C@@H]4NC(C4COC4)=O)=O)c3)c2C1 Chemical compound CC1(C)C[n]2ncc(-c3c(C)cnc(NC([C@@H](CCC4)C[C@@H]4NC(C4COC4)=O)=O)c3)c2C1 BNMSUGRKZJRLFE-FUHWJXTLSA-N 0.000 description 1
- NDQRCUOYOAPFLR-DLBZAZTESA-N CC1(C)C[n]2ncc(-c3cc(NC([C@@H](CCC4)C[C@@H]4NC(C)=O)=O)ncc3C)c2C1 Chemical compound CC1(C)C[n]2ncc(-c3cc(NC([C@@H](CCC4)C[C@@H]4NC(C)=O)=O)ncc3C)c2C1 NDQRCUOYOAPFLR-DLBZAZTESA-N 0.000 description 1
- XXQQVRHUSGAJDV-LSDHHAIUSA-N CC1(C)C[n]2ncc(-c3cc(NC([C@@H](CCC4)C[C@@H]4NC(C)=O)=O)ncn3)c2C1 Chemical compound CC1(C)C[n]2ncc(-c3cc(NC([C@@H](CCC4)C[C@@H]4NC(C)=O)=O)ncn3)c2C1 XXQQVRHUSGAJDV-LSDHHAIUSA-N 0.000 description 1
- QSTQLWWICNAVCS-UONOGXRCSA-N CC1(C)C[n]2ncc(-c3cc(NCC([C@H](C4)C=CC[C@H]4N)=O)ncc3F)c2C1 Chemical compound CC1(C)C[n]2ncc(-c3cc(NCC([C@H](C4)C=CC[C@H]4N)=O)ncc3F)c2C1 QSTQLWWICNAVCS-UONOGXRCSA-N 0.000 description 1
- VTGLXGMEJLXEHX-LSDHHAIUSA-N CC1(C)C[n]2ncc(-c3ccnc(NC([C@@H](CCC4)C[C@@H]4N)=O)c3)c2C1 Chemical compound CC1(C)C[n]2ncc(-c3ccnc(NC([C@@H](CCC4)C[C@@H]4N)=O)c3)c2C1 VTGLXGMEJLXEHX-LSDHHAIUSA-N 0.000 description 1
- JJAODUJOYOMWDG-UHFFFAOYSA-N CC1(C)C[n]2ncc(B3OC(C)(C)C(C)(C)O3)c2C1 Chemical compound CC1(C)C[n]2ncc(B3OC(C)(C)C(C)(C)O3)c2C1 JJAODUJOYOMWDG-UHFFFAOYSA-N 0.000 description 1
- QXHPGMLRFVKANA-UHFFFAOYSA-N CC1(C)C[n]2ncc(Br)c2C1 Chemical compound CC1(C)C[n]2ncc(Br)c2C1 QXHPGMLRFVKANA-UHFFFAOYSA-N 0.000 description 1
- VFWPYISPOCRBHF-UHFFFAOYSA-N CC1(C)C[n]2ncc(S3OC(C)(C)C(C)(C)O3)c2C1 Chemical compound CC1(C)C[n]2ncc(S3OC(C)(C)C(C)(C)O3)c2C1 VFWPYISPOCRBHF-UHFFFAOYSA-N 0.000 description 1
- LJCFTIMGDJYWHD-UHFFFAOYSA-N CC1(C)OB(c2c(CCC3)[n]3nc2)OC1(C)C Chemical compound CC1(C)OB(c2c(CCC3)[n]3nc2)OC1(C)C LJCFTIMGDJYWHD-UHFFFAOYSA-N 0.000 description 1
- KJIVFEQWJYSIIP-UHFFFAOYSA-N CC1(C)OB(c2c3OCCC[n]3nc2)OC1(C)C Chemical compound CC1(C)OB(c2c3OCCC[n]3nc2)OC1(C)C KJIVFEQWJYSIIP-UHFFFAOYSA-N 0.000 description 1
- KZJSUGHOGMRTFQ-JQXSQYPDSA-N CC1C[n]2ncc(-c(cc(NC([C@@H](CCC3)C[C@@H]3NC(C)=O)=O)nc3)c3Cl)c2C1 Chemical compound CC1C[n]2ncc(-c(cc(NC([C@@H](CCC3)C[C@@H]3NC(C)=O)=O)nc3)c3Cl)c2C1 KZJSUGHOGMRTFQ-JQXSQYPDSA-N 0.000 description 1
- KZJSUGHOGMRTFQ-BLZCZZARSA-N CC1C[n]2ncc(-c3cc(NC([C@@H](CCC4)CC4NC(C)=O)=O)ncc3Cl)c2C1 Chemical compound CC1C[n]2ncc(-c3cc(NC([C@@H](CCC4)CC4NC(C)=O)=O)ncc3Cl)c2C1 KZJSUGHOGMRTFQ-BLZCZZARSA-N 0.000 description 1
- LRDQMNHYYHKGTO-UHFFFAOYSA-N CC1C[n]2nccc2C1 Chemical compound CC1C[n]2nccc2C1 LRDQMNHYYHKGTO-UHFFFAOYSA-N 0.000 description 1
- MSVDQQUSUFLNEP-UHFFFAOYSA-N CC1Cc2c(B3OC(C)(C)C(C)(C)O3)cn[n]2CC1 Chemical compound CC1Cc2c(B3OC(C)(C)C(C)(C)O3)cn[n]2CC1 MSVDQQUSUFLNEP-UHFFFAOYSA-N 0.000 description 1
- KNNSDIRXYNZRPT-UHFFFAOYSA-N CCOC(C(C)(C)C[n]1nccc1)=O Chemical compound CCOC(C(C)(C)C[n]1nccc1)=O KNNSDIRXYNZRPT-UHFFFAOYSA-N 0.000 description 1
- HZWFFFWPXQJIEA-UHFFFAOYSA-N CCOC(c1ccn[n]1CCCCC(OC)=O)=O Chemical compound CCOC(c1ccn[n]1CCCCC(OC)=O)=O HZWFFFWPXQJIEA-UHFFFAOYSA-N 0.000 description 1
- XPYPKZBZUMCFEU-UHFFFAOYSA-N CCOC(c1n[n](Cc2ccccc2)cc1)=O Chemical compound CCOC(c1n[n](Cc2ccccc2)cc1)=O XPYPKZBZUMCFEU-UHFFFAOYSA-N 0.000 description 1
- WIFYRCPNPBWODK-UHFFFAOYSA-N CN(CC[n]1nc2)Cc1c2Br Chemical compound CN(CC[n]1nc2)Cc1c2Br WIFYRCPNPBWODK-UHFFFAOYSA-N 0.000 description 1
- QYGNDKJRRNVSEC-UHFFFAOYSA-N COC1=NCCC1 Chemical compound COC1=NCCC1 QYGNDKJRRNVSEC-UHFFFAOYSA-N 0.000 description 1
- GPDLABULMNHRGK-DZGCQCFKSA-N Cc1c(C)cnc(NC([C@@H](CCC2)C[C@@H]2NC(C2COC2)=O)=O)c1 Chemical compound Cc1c(C)cnc(NC([C@@H](CCC2)C[C@@H]2NC(C2COC2)=O)=O)c1 GPDLABULMNHRGK-DZGCQCFKSA-N 0.000 description 1
- ZSUAJRFGCWDEKK-UHFFFAOYSA-N Cc1cc2ccn[n]2cc1 Chemical compound Cc1cc2ccn[n]2cc1 ZSUAJRFGCWDEKK-UHFFFAOYSA-N 0.000 description 1
- YQEVNNXZEKRMBM-UHFFFAOYSA-N Fc(c(-c1c(CCCC2)[n]2nc1)c1)cnc1Cl Chemical compound Fc(c(-c1c(CCCC2)[n]2nc1)c1)cnc1Cl YQEVNNXZEKRMBM-UHFFFAOYSA-N 0.000 description 1
- HMUHOYPYMGDIFZ-UHFFFAOYSA-N Fc(c(-c1c(CCCCC2)[n]2nc1)c1)cnc1Cl Chemical compound Fc(c(-c1c(CCCCC2)[n]2nc1)c1)cnc1Cl HMUHOYPYMGDIFZ-UHFFFAOYSA-N 0.000 description 1
- GENMQVWALZOJDU-STQMWFEESA-N N[C@@H](CCC1)C[C@H]1C(Nc(nc1)cc(-c2c(CCCC3)[n]3nc2)c1Cl)=O Chemical compound N[C@@H](CCC1)C[C@H]1C(Nc(nc1)cc(-c2c(CCCC3)[n]3nc2)c1Cl)=O GENMQVWALZOJDU-STQMWFEESA-N 0.000 description 1
- KSSKEUMEVHVNEE-LSDHHAIUSA-N N[C@H](CCC1)C[C@H]1C(Nc1cc(-c2c(CCCC3)[n]3nc2)ccn1)=O Chemical compound N[C@H](CCC1)C[C@H]1C(Nc1cc(-c2c(CCCC3)[n]3nc2)ccn1)=O KSSKEUMEVHVNEE-LSDHHAIUSA-N 0.000 description 1
- NPTGTSAQEXTQQK-JGVFFNPUSA-N N[C@H](CCC1)C[C@H]1C(Nc1ncnc(Cl)c1)=O Chemical compound N[C@H](CCC1)C[C@H]1C(Nc1ncnc(Cl)c1)=O NPTGTSAQEXTQQK-JGVFFNPUSA-N 0.000 description 1
- VIZMARKIEQIMIG-UHFFFAOYSA-N Nc(nc1)cc(Br)c1Cl Chemical compound Nc(nc1)cc(Br)c1Cl VIZMARKIEQIMIG-UHFFFAOYSA-N 0.000 description 1
- PMLVDYBLXQYWLI-UHFFFAOYSA-N Nc(nc1)cc(I)c1Cl Chemical compound Nc(nc1)cc(I)c1Cl PMLVDYBLXQYWLI-UHFFFAOYSA-N 0.000 description 1
- XFDUHJPVQKIXHO-UHFFFAOYSA-N Nc1cccc(C(O)=O)c1 Chemical compound Nc1cccc(C(O)=O)c1 XFDUHJPVQKIXHO-UHFFFAOYSA-N 0.000 description 1
- CFSLZIQYIPODLL-UHFFFAOYSA-N O=C(C1CCCCC1)Nc(cc1-c2cnc3[n]2CCCC3)ncc1Cl Chemical compound O=C(C1CCCCC1)Nc(cc1-c2cnc3[n]2CCCC3)ncc1Cl CFSLZIQYIPODLL-UHFFFAOYSA-N 0.000 description 1
- QRDGLFWYBFTZFP-UHFFFAOYSA-N O=C1c2ccn[n]2CCC1 Chemical compound O=C1c2ccn[n]2CCC1 QRDGLFWYBFTZFP-UHFFFAOYSA-N 0.000 description 1
- YFZJCYRJIJGWDX-UHFFFAOYSA-N O=C1c2ccn[n]2CCCC1 Chemical compound O=C1c2ccn[n]2CCCC1 YFZJCYRJIJGWDX-UHFFFAOYSA-N 0.000 description 1
- BMBFFHUQGZQFKW-UHFFFAOYSA-N OB(c1cnc2[n]1CCC2)O Chemical compound OB(c1cnc2[n]1CCC2)O BMBFFHUQGZQFKW-UHFFFAOYSA-N 0.000 description 1
- CZPRLVUTBZKCJG-UHFFFAOYSA-N OC(c1n[n](Cc2ccccc2)cc1)=O Chemical compound OC(c1n[n](Cc2ccccc2)cc1)=O CZPRLVUTBZKCJG-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Polyesters Or Polycarbonates (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Detergent Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562185852P | 2015-06-29 | 2015-06-29 | |
US62/185,852 | 2015-06-29 | ||
PCT/EP2016/064899 WO2017001354A1 (en) | 2015-06-29 | 2016-06-27 | Polycyclic amide derivatives as cdk9 inhibitors |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2018522869A JP2018522869A (ja) | 2018-08-16 |
JP2018522869A5 JP2018522869A5 (pl) | 2019-07-18 |
JP6997627B2 true JP6997627B2 (ja) | 2022-01-17 |
Family
ID=56292699
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017567737A Active JP6997627B2 (ja) | 2015-06-29 | 2016-06-27 | Cdk9阻害剤としての多環式アミド誘導体 |
Country Status (36)
Country | Link |
---|---|
US (4) | US9845331B2 (pl) |
EP (2) | EP3539961B1 (pl) |
JP (1) | JP6997627B2 (pl) |
KR (1) | KR102663113B1 (pl) |
CN (1) | CN107873028B (pl) |
AR (1) | AR105179A1 (pl) |
AU (1) | AU2016286200B2 (pl) |
BR (1) | BR122019013677B1 (pl) |
CA (1) | CA2989499C (pl) |
CL (1) | CL2017003306A1 (pl) |
CO (1) | CO2017013713A2 (pl) |
CR (2) | CR20210297A (pl) |
CY (2) | CY1122111T1 (pl) |
DK (2) | DK3313838T3 (pl) |
DO (2) | DOP2017000295A (pl) |
EA (1) | EA035383B1 (pl) |
ES (2) | ES2728356T3 (pl) |
HR (2) | HRP20211970T1 (pl) |
HU (2) | HUE043440T2 (pl) |
IL (1) | IL256393B (pl) |
LT (2) | LT3539961T (pl) |
ME (1) | ME03404B (pl) |
MX (1) | MX371034B (pl) |
NI (1) | NI201700174A (pl) |
PE (1) | PE20180530A1 (pl) |
PH (1) | PH12017502334A1 (pl) |
PL (2) | PL3313838T3 (pl) |
PT (2) | PT3313838T (pl) |
RS (2) | RS58712B1 (pl) |
SI (2) | SI3313838T1 (pl) |
SV (1) | SV2017005598A (pl) |
TN (1) | TN2017000486A1 (pl) |
TR (1) | TR201909286T4 (pl) |
TW (1) | TWI723028B (pl) |
WO (1) | WO2017001354A1 (pl) |
ZA (1) | ZA201800563B (pl) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2020003270A (es) | 2017-09-25 | 2020-07-20 | Astrazeneca Ab | Combinacion de un inhibidor de btk y un inhibidor de cdk9 para tratar el cancer. |
EP3694506B1 (en) * | 2017-10-09 | 2023-08-02 | Merck Sharp & Dohme LLC | Novel substituted phenyloxetane and phenyltetrahydrofuran compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
CN108129288B (zh) * | 2017-12-27 | 2021-01-22 | 上海毕得医药科技股份有限公司 | 一种反式-3-羟基环丁基甲酸的合成方法 |
TWI810397B (zh) | 2018-11-14 | 2023-08-01 | 瑞典商阿斯特捷利康公司 | 治療癌症之方法 |
BR112022004327A2 (pt) * | 2019-09-11 | 2022-05-31 | Prelude Therapeutics Inc | Inibidores de cdk e seu uso como fármacos |
AU2020401999B2 (en) * | 2019-12-09 | 2024-01-18 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Compound as cyclin-dependent kinase 9 inhibitor and use thereof |
US20230219961A1 (en) * | 2020-05-12 | 2023-07-13 | Suzhou Alphama Biotechnology Co., Ltd. | Pyridine acetamide derivative serving as CDK inhibitor, and preparation method therefor and use thereof |
WO2021227904A1 (zh) | 2020-05-12 | 2021-11-18 | 苏州阿尔脉生物科技有限公司 | 一种作为cdk9抑制剂的多环酰胺类衍生物、其制备方法及用途 |
JP2023542065A (ja) | 2020-06-24 | 2023-10-05 | アストラゼネカ ユーケー リミテッド | 抗体-薬物複合物及びcdk9阻害剤の組み合わせ |
CN115843296B (zh) | 2020-08-07 | 2024-03-08 | 南京迈晟科技有限责任公司 | Cdk9抑制剂及其用途 |
TWI809330B (zh) * | 2020-11-20 | 2023-07-21 | 大陸商勁方醫藥科技(上海)有限公司 | Cdk9抑制劑的多晶型物及其製法和用途 |
CN115381824A (zh) * | 2021-05-24 | 2022-11-25 | 石药集团中奇制药技术(石家庄)有限公司 | 周期蛋白依赖性激酶9抑制剂的用途 |
CN115381823A (zh) * | 2021-05-24 | 2022-11-25 | 石药集团中奇制药技术(石家庄)有限公司 | 一种周期蛋白依赖性激酶9抑制剂的用途 |
CN117813289A (zh) * | 2021-07-14 | 2024-04-02 | 上海海雁医药科技有限公司 | 吡唑衍生物及其中间体和制备方法 |
US20230279016A1 (en) * | 2021-12-23 | 2023-09-07 | The Katholieke Universiteit Leuven | Tetrahydropyrazolopyrimidines and Related Analogs for Inhibiting YAP/TAZ-TEAD |
KR20240025485A (ko) | 2022-08-17 | 2024-02-27 | 한국화학연구원 | Cdk2 및/또는 cdk9의 억제 또는 분해용 화합물 및 이들의 의약 용도 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008133192A1 (ja) | 2007-04-19 | 2008-11-06 | Takeda Pharmaceutical Company Limited | 縮合イミダゾール化合物およびその用途 |
WO2011101640A1 (en) | 2010-02-19 | 2011-08-25 | Medical Research Council Technology | Fused heterocyclic compounds for use in the treatment of malaria |
WO2011124539A1 (de) | 2010-04-07 | 2011-10-13 | Bayer Cropscience Ag | Bicyclische pyridinylpyrazole |
WO2012101063A1 (en) | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyridine biaryl compounds and their uses |
WO2013050434A1 (en) | 2011-10-06 | 2013-04-11 | Bayer Intellectual Property Gmbh | Heterocyclylpyri(mi)dinylpyrazole |
WO2014160017A1 (en) | 2013-03-13 | 2014-10-02 | Abbvie Inc. | Pyridine cdk9 kinase inhibitors |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8436007B2 (en) | 2007-04-24 | 2013-05-07 | Ingenium Pharmaceuticals Gmbh | Inhibitors of protein kinases |
EP2137166B1 (en) | 2007-04-24 | 2012-05-30 | Ingenium Pharmaceuticals GmbH | 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases |
WO2008129071A1 (en) | 2007-04-24 | 2008-10-30 | Ingenium Pharmaceuticals Gmbh | Inhibitors of protein kinases |
US8389521B2 (en) | 2007-04-24 | 2013-03-05 | Ingenium Pharmaceuticals Gmbh | Inhibitors of protein kinases |
WO2008132138A1 (en) | 2007-04-25 | 2008-11-06 | Ingenium Pharmaceuticals Gmbh | Derivatives of 4,6-disubstituted aminopyrimidines |
CN104151293A (zh) | 2007-10-12 | 2014-11-19 | 阿斯利康公司 | 蛋白激酶抑制剂 |
CA2771568A1 (en) | 2009-09-04 | 2011-03-10 | Novartis Ag | Heteroaryl compounds as kinase inhibitors |
US20110113038A1 (en) | 2009-11-12 | 2011-05-12 | International Business Machines Corporation | Search term security |
JP2013521324A (ja) | 2010-03-10 | 2013-06-10 | インゲニウム ファーマシューティカルズ ジーエムビーエイチ | プロテインキナーゼの阻害剤 |
WO2012066065A1 (en) | 2010-11-17 | 2012-05-24 | Novartis Ag | Phenyl-heteroaryl amine compounds and their uses |
WO2012101064A1 (en) | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyrimidine biaryl compounds as protein kinase inhibitors |
EP2668162A1 (en) * | 2011-01-28 | 2013-12-04 | Novartis AG | Substituted bi-heteroaryl compounds as cdk9 inhibitors and their uses |
EP2970268A1 (en) | 2013-03-13 | 2016-01-20 | AbbVie Inc. | Cdk9 kinase inhibitors |
TW201444836A (zh) | 2013-03-14 | 2014-12-01 | Abbvie Inc | 吡咯并[2,3-b]吡啶cdk9激酶抑制劑 |
WO2014160028A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | Pyrrolopyrimindine cdk9 kinase inhibitors |
-
2016
- 2016-06-27 TN TNP/2017/000486A patent/TN2017000486A1/en unknown
- 2016-06-27 HR HRP20211970TT patent/HRP20211970T1/hr unknown
- 2016-06-27 RS RS20190564A patent/RS58712B1/sr unknown
- 2016-06-27 KR KR1020187002262A patent/KR102663113B1/ko active IP Right Grant
- 2016-06-27 LT LTEP19165726.1T patent/LT3539961T/lt unknown
- 2016-06-27 BR BR122019013677-7A patent/BR122019013677B1/pt active IP Right Grant
- 2016-06-27 PT PT16733459T patent/PT3313838T/pt unknown
- 2016-06-27 CN CN201680029447.9A patent/CN107873028B/zh active Active
- 2016-06-27 WO PCT/EP2016/064899 patent/WO2017001354A1/en active Application Filing
- 2016-06-27 HU HUE16733459A patent/HUE043440T2/hu unknown
- 2016-06-27 PL PL16733459T patent/PL3313838T3/pl unknown
- 2016-06-27 AU AU2016286200A patent/AU2016286200B2/en active Active
- 2016-06-27 PL PL19165726T patent/PL3539961T3/pl unknown
- 2016-06-27 CR CR20210297A patent/CR20210297A/es unknown
- 2016-06-27 CA CA2989499A patent/CA2989499C/en active Active
- 2016-06-27 DK DK16733459.8T patent/DK3313838T3/da active
- 2016-06-27 HU HUE19165726A patent/HUE057343T2/hu unknown
- 2016-06-27 RS RS20220005A patent/RS62781B1/sr unknown
- 2016-06-27 PT PT191657261T patent/PT3539961T/pt unknown
- 2016-06-27 ES ES16733459T patent/ES2728356T3/es active Active
- 2016-06-27 ES ES19165726T patent/ES2902148T3/es active Active
- 2016-06-27 LT LTEP16733459.8T patent/LT3313838T/lt unknown
- 2016-06-27 TR TR2019/09286T patent/TR201909286T4/tr unknown
- 2016-06-27 CR CR20170596A patent/CR20170596A/es unknown
- 2016-06-27 EA EA201890094A patent/EA035383B1/ru not_active IP Right Cessation
- 2016-06-27 ME MEP-2019-138A patent/ME03404B/me unknown
- 2016-06-27 SI SI201630247T patent/SI3313838T1/sl unknown
- 2016-06-27 PE PE2017002874A patent/PE20180530A1/es unknown
- 2016-06-27 MX MX2017016244A patent/MX371034B/es active IP Right Grant
- 2016-06-27 EP EP19165726.1A patent/EP3539961B1/en active Active
- 2016-06-27 US US15/193,826 patent/US9845331B2/en active Active
- 2016-06-27 SI SI201631427T patent/SI3539961T1/sl unknown
- 2016-06-27 EP EP16733459.8A patent/EP3313838B1/en active Active
- 2016-06-27 DK DK19165726.1T patent/DK3539961T3/da active
- 2016-06-27 JP JP2017567737A patent/JP6997627B2/ja active Active
- 2016-06-28 TW TW105120362A patent/TWI723028B/zh active
- 2016-06-28 AR ARP160101956A patent/AR105179A1/es unknown
-
2017
- 2017-12-06 US US15/833,277 patent/US10717746B2/en active Active
- 2017-12-12 DO DO2017000295A patent/DOP2017000295A/es unknown
- 2017-12-15 PH PH12017502334A patent/PH12017502334A1/en unknown
- 2017-12-18 IL IL256393A patent/IL256393B/en unknown
- 2017-12-20 SV SV2017005598A patent/SV2017005598A/es unknown
- 2017-12-21 CL CL2017003306A patent/CL2017003306A1/es unknown
- 2017-12-22 NI NI201700174A patent/NI201700174A/es unknown
- 2017-12-28 CO CONC2017/0013713A patent/CO2017013713A2/es unknown
-
2018
- 2018-01-26 ZA ZA2018/00563A patent/ZA201800563B/en unknown
- 2018-09-25 DO DO2018000207A patent/DOP2018000207A/es unknown
-
2019
- 2019-04-19 HR HRP20190748TT patent/HRP20190748T1/hr unknown
- 2019-06-19 CY CY20191100636T patent/CY1122111T1/el unknown
-
2020
- 2020-07-17 US US16/931,786 patent/US11352369B2/en active Active
-
2021
- 2021-12-22 CY CY20211101125T patent/CY1125066T1/el unknown
-
2022
- 2022-04-27 US US17/660,935 patent/US20220340592A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008133192A1 (ja) | 2007-04-19 | 2008-11-06 | Takeda Pharmaceutical Company Limited | 縮合イミダゾール化合物およびその用途 |
WO2011101640A1 (en) | 2010-02-19 | 2011-08-25 | Medical Research Council Technology | Fused heterocyclic compounds for use in the treatment of malaria |
WO2011124539A1 (de) | 2010-04-07 | 2011-10-13 | Bayer Cropscience Ag | Bicyclische pyridinylpyrazole |
WO2012101063A1 (en) | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyridine biaryl compounds and their uses |
WO2013050434A1 (en) | 2011-10-06 | 2013-04-11 | Bayer Intellectual Property Gmbh | Heterocyclylpyri(mi)dinylpyrazole |
WO2014160017A1 (en) | 2013-03-13 | 2014-10-02 | Abbvie Inc. | Pyridine cdk9 kinase inhibitors |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6997627B2 (ja) | Cdk9阻害剤としての多環式アミド誘導体 | |
KR102388208B1 (ko) | 암을 치료하기 위한 거대 환형 mcl1 억제제 | |
JP5770102B2 (ja) | 複素環化合物と使用方法 | |
TW202246255A (zh) | Cdk抑制劑及其使用方法 | |
US8796289B2 (en) | Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases | |
TW201938566A (zh) | 囊性纖維化跨膜傳導調節因子之調節劑、醫藥組合物、治療方法及製造該調節劑之方法 | |
TW202128685A (zh) | 作為fgfr抑制劑之雙環雜環 | |
EP3288931B2 (en) | Certain protein kinase inhibitor | |
KR20140096100A (ko) | 이환 피페라진 화합물 | |
CA2864142A1 (en) | Pyridopyrimidinone inhibitors of kinases | |
JP2021102619A (ja) | ブロモドメイン阻害剤 | |
US20230339977A1 (en) | Substituted heteroaryl compound, and composition and application thereof | |
BR112017027394B1 (pt) | Composto, forma cristalina, composição farmacêutica e uso do mesmo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190613 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190613 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200528 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200602 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200901 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210216 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210420 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210715 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210813 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20211130 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20211217 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6997627 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |